Il-Jin Kim, Ph.D.

Assistant Professor
Director of Applied Genomics,
Thoracic Oncology Laboratory
Principal Investigator, Kim Lab

Contact Information

Thoracic Oncology Laboratory
UCSF Helen Diller Family Comprehensive Cancer Center
2340 Sutter St, Room N225
San Francisco, CA 94143-1724
(415) 476-9096 
  • 1994-99, College of Veterinary Medicine , Seoul National University, Korea, B.S., D.V.M. (Magna Cum Laude)
  • 1999-01, College of Medicine, Seoul National University, Korea, M.S. Tumor Biology
  • 2001-03, College of Medicine, Seoul National University, Korea, Ph.D. Tumor Biology
  • 2003-04, Postdoctoral Researcher, Seoul National University, Korea, Cancer Center
  • 2005-06, Senior Postdoctoral Researcher, Seoul National University, Korea, Cancer Center
  • 2007-2008  Post Doctoral Fellow, UCSF Helen Diller Family Comprehensive Cancer Center
  • Thoracic Oncology Laboratory
  • Thoracic Oncology Program
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • UCSF Department of Surgery
  • Development of high-throughput assays for prognosis and predictive analysis in lung cancer and mesothelioma
  • Development of multi-dimensional assays for early detection of lung cancer
  • Drug development, specifically novel targeted agents for treatment of thoracic malignancies
  • Identification of novel fusion genes in lung cancer and mesothelioma
  • Interplay of mutation (genetic) and methylation (epigenetic) analysis in lung carcinogenesis
  • Utilization of system genetics to identify novel diagnostic and therapeutic molecular targets

Dr. Il-Jin Kim is a Principal Investigator and Director of Applied Genomics in the UCSF Thoracic Oncology Lab and Director of the Kim Lab.  His work focuses on the identification of novel diagnostic and therapeutic markers in lung cancer and mesothelioma.  Dr. Kim investigates human cancers using state-of-the-art technologies including next-generation sequencing (NGS) and system genetics, Dr. Kim has developed several innovative microarrays (RET, beta-catenin, K-ras, and BRAF) and pioneered new methods of high-throughput mutation screening for which he holds numerous patents. 

Dr. Kim graduated the College of Veterinary Medicine , Seoul National University with a B.S. and D.V.M., and an M.S. and Ph.D. in Tumor Biology from the College of Medicine at Seoul National University. In 2008, Dr. Kim came to UCSF as a post-doctoral fellow and joined the UCSF faculty as an Assistant Adjunct Professor in the Department of Surgery.

Dr. Il-Jin Kim served as a group leader of the Korean Hereditary Tumor Registry from 2003-2006, an organization of which he has been a member since 1999. As group leader, he led a project that screened approximately 1,000 patients from 400 families, looking at 12 inherited cancer syndromes. He has three times received awards for development of genetic assays by the AACR (American Association for Cancer Research).

His research and paper for the 'Prediction of response to preoperative chemoradiotherapy in colorectal cancer patients' was named the best publication of 2007 by the journal "Dis Colon Rectum", the award given at the 2008 ASCRS (American Society of Colon and Rectal Surgeons) Annual Meeting. He is now a principal Investigator in the Thoracic Oncology Laboratory at UCSF.




  • Mesothelioma Research Grant Award, Mesothelioma Applied Research Foundation, 2013-2014
  • Uniting Against Lung Cancer Research Grant Award, Uniting Against Lung Cancer , 2012-2014
  • Impact Paper of the Year Award, The American Society of Colon and Rectal Surgeons , 2008
  • AACR ITO-EN Scholar-In-Training Award, American Association for Cancer Research , 2006
  • GlaxoSmithKline (GSK) Award, Korean Cancer Association, 2005
  • Best Research Award, National Cancer Center, Korea, 2005
  • AACR ITO-EN Scholar-In-Training Award, American Association for Cancer Research , 2005
  • National Cancer Center Travel Award to AACR annual meeting, National Cancer Center, Korea, 2004
  • Best Research Award, Korea Cancer Research Foundation, 2004
  • Outstanding Science and Technology Publication Award, , Korean Federation of Science and Technology Societies, 2004
  • BK21 (Brain Korea 21) Postdoctoral Fellowship, BK21, Korea, 2003-2004
  • Best Research Award, Korea Cancer Research Foundation, 2003
  • AACR ITO-EN Scholar-In-Training Award , American Association for Cancer Research, 2003
  • Best Research Award, Korea Cancer Research Foundation, 2002
  • Graduation with Honors (Magna Cum Laude) , Seoul National University, Korea, 1999
  • Presidential Honors Student , Seoul National University, Korea, 1997
View all

Dr. Il-Jin Kim has focused his career on three important cancer-related areas:

  1. Cancer genetics and genomics
  2. Early detection
  3. Cancer prevention. Dr. Kim has published approximately 55 papers in these areas. He has also been granted three patents for mutation detection methods. Projects included in these areas include: genetic screening in hereditary (familial) cancers to distinguishing carriers from non-carriers, development of new genetic screening methods for cancer prevention, and genome-wide gene expression microarray analysis.

Building on the work of  "Lung Cancer System Genetics" Project, a 5-year research collaboration with the Thoracic Oncology Lab funded by The  Bonnie J. Addario Lung Cancer Foundation, the Kim Lab employs  sophisticated system genetics/genomics approaches in lung and other human cancers to develop predictive and prognostic molecular markers for diagnostic and  therapeutic application. 

The Kim lab studies genome-wide gene expression, DNA copy number, mutation, fusions, and any other genetic changes in lung cancer. His lab has identified several novel molecular targets in normal and matched adenocarcinoma tissue, and is now working on functional and biological validation of these markers. This research is being used to develop novel therapeutic drugs and diagnostic assays for lung adenocarcinoma.

  • Mesothelioma Applied Research Foundation, Mesothelioma Research Grant Award, 2013-14
Most recent publications from a total of 67
  1. Zhang S, Yang YL, Wang Y, You B, Dai Y, Chan G, Hsieh D, Kim IJ, Fang L, Au A, Stoppler HJ, Xu Z, Jablons DM, You L. CK2¿, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells. J Exp Clin Cancer Res. 2014 Nov 25; 33(1):93. View in PubMed
  2. Fang LT, Lee S, Choi H, Kim HK, Jew G, Kang HC, Chen L, Jablons D, Kim IJ. Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis. Int J Oncol. 2014 Jan; 44(1):211-21. View in PubMed
  3. Kim HK, Jablons DM, Kim IJ. Multistep Progression from Atypical Adenomatous Hyperplasia to Lung Adenocarcinoma: Clinico-Pathologic, Epigenetic and Genetic Aspects. J Surgery. 2013; 1(1):10. View in PubMed
  4. Bosco-Clément G, Zhang F, Chen Z, Zhou HM, Li H, Mikami I, Hirata T, Yagui-Beltran A, Lui N, Do HT, Cheng T, Tseng HH, Choi H, Fang LT, Kim IJ, Yue D, Wang C, Zheng Q, Fujii N, Mann M, Jablons DM, He B. Targeting Gli transcription activation by small molecule suppresses tumor growth. Oncogene. 2014 Apr 17; 33(16):2087-97. View in PubMed
  5. Kang HC, Quigley DA, Kim IJ, Wakabayashi Y, Ferguson-Smith MA, D'Alessandro M, Birgitte Lane E, Akhurst RJ, Goudie DR, Balmain A. Multiple self-healing squamous epithelioma (MSSE): rare variants in an adjacent region of chromosome 9q22.3 to known TGFBR1 mutations suggest a digenic or multilocus etiology. J Invest Dermatol. 2013 Jul; 133(7):1907-10. View in PubMed
  6. Kim IJ, Quigley D, To MD, Pham P, Lin K, Jo B, Jen KY, Raz D, Kim J, Mao JH, Jablons D, Balmain A. Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. Nat Commun. 2013; 4:1701. View in PubMed
  7. Mulvihill MS, Kwon YW, Lee S, Fang LT, Choi H, Ray R, Kang HC, Mao JH, Jablons D, Kim IJ. Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells. PLoS One. 2012; 7(8):e42264. View in PubMed
  8. Kim JW, Lee S, Lui N, Choi H, Mulvihill M, Fang LT, Kang HC, Kwon YW, Jablons D, Kim IJ. A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease. Oncol Rep. 2012 Oct; 28(4):1225-30. View in PubMed
  9. Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, Hu LM, Xu Z, Long H, Jablons DM, You L. Inhibition of CK2a down-regulates Hedgehog/Gli signaling leading to a reduction of a stem-like side population in human lung cancer cells. PLoS One. 2012; 7(6):e38996. View in PubMed
  10. Kwon YW, Kim IJ, Wu D, Lu J, Stock WA, Liu Y, Huang Y, Kang HC, DelRosario R, Jen KY, Perez-Losada J, Wei G, Balmain A, Mao JH. Pten regulates Aurora-A and cooperates with Fbxw7 in modulating radiation-induced tumor development. Mol Cancer Res. 2012 Jun; 10(6):834-44. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Il-Jin Kim, Ph.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.